Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit.~* Main Study only: Body mass index (BMI) \> 25 kg/m\^2 (unless the patient has biopsy-proven NASH documented within the last 2 years).~* Main Study only: Must have confirmation of ≥ 10% liver fat content on magnetic resonance imaging- proton density fat fraction (MRI-PDFF) at screening.~* Main Study only: Biopsy-proven NASH. Must have had a liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:~  * Steatosis (scored 0 to 3),~ * Ballooning degeneration (scored 0 to 2), and~ * Lobular inflammation (scored 0 to 3)~* Cohort C only: FibroScan® measurement \> 13.1 kPa.~* Cohort C only: Cirrhosis due to NASH. Liver biopsy consistent with F4 fibrosis according to the NAS system, confirmed by the central or local reader.~Exclusion Criteria:~* Weight gain or loss \> 5% in the 3 months prior to randomization or \> 10% in the 6 months prior to screening.~* Type 1 and insulin-dependent Type 2 diabetes.~* Poorly controlled hypertension (blood pressure \> 160/100).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EFX Dose 1 (Type: EXPERIMENTAL): Main Study
- EFX Dose 2 (Type: EXPERIMENTAL): Main Study
- EFX Dose 3 (Type: EXPERIMENTAL): Main Study
- Placebo (Type: PLACEBO_COMPARATOR): Main Study
- EFX Dose (Cohort C) (Type: EXPERIMENTAL): None
- Placebo (Cohort C) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).